Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221) (2020)

Peer-Reviewed Study · Ambrosone CB, Zirpolo GR, Hutson AD, et al. · March 10, 2020

Ambrosone CB et al., 2020-03-10: Prospective ancillary study to SWOG S0221 (n=1,134) linking antioxidant supplement use during chemotherapy, explicitly including coenzyme Q10, to higher hazards of recurrence and death; both confidence intervals cross 1.

There were indications that use of any antioxidant supplement (vitamins A, C, and E; carotenoids; coenzyme Q10) both before and during treatment was associated with an increased hazard of recurrence (adjusted hazard ratio [adjHR], 1.41; 95% CI, 0.98 to 2.04; P = .06) and, to a lesser extent, death (adjHR, 1.40; 95% CI, 0.90 to 2.18; P = .14).

Abstract, Results

Ambrosone CB et al., 2020-03-10: Prospective ancillary study to SWOG S0221 (n=1,134) linking antioxidant supplement use during chemotherapy, explicitly including coenzyme Q10, to higher hazards of recurrence and death; both confidence intervals cross 1. Study type: controlled study.